RNS Number : 3917R
ValiRx PLC
29 June 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Appointment of Director

London, UK, *29 June 2020*: ValiRx (AIM:VAL) announces that, further to the announcement of 27 May 2020, Kevin Cox has been appointed as Non-executive Chairman of the Company with effect from 26 June 2020.

The following information is disclosed in respect of Dr Kevin Paul Cox (age 61) pursuant to Schedule 2(g) of the AIM Rules for Companies:

Current directorships and partnerships	**Directorships and partnerships held in the past five years**
Aurora CBT Limited	Bioindustry Association
Biotaspheric Limited	Imanova Limited
Biorelate Limited	Perenna Consulting Limited
British Neuroscience Association Limited	
The Griffin Practice Limited	

Mr Kevin Cox does not hold any ordinary shares nor options over ordinary shares in the Company.

There is no further information which is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of Mr Kevin Cox.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

***** ENDS *****

For more information, please contact:

ValiRx plc **Tel: +44 (0) 20 7073 2628**
www.valirx.com
Suzanne Dilly Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) **Tel: +44 (0) 20 7213 0880**
Liam Murray / Jo Turner / Ludovico Lazzaretti

Peterhouse Capital Limited (Sole Broker) **Tel: +44 (0) 20 7469 0930**
Duncan Vasey / Lucy Williams / Eran Zucker

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer.

The Company's business model focuses on identifying and in-licensing early stage projects, adding value through scientific development and then out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the Company reduces risk while increasing the potential for realising value.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAFLFSIRFIAFII